Parkinson's Disease Awareness & Support

23/07/2026

Just curious where everyone is from? I’m from North Andover, Massachusetts. Just wondering if there are enough people in my area, it would be nice to set up time to meet for coffee or something at a Panera or Starbucks maybe once a month.

23/07/2026

I will not be silent ... I will not go down in silence and alone like so many that have with PD.... we don't talk about this enough; the social isolation ... my brothers and sisters this is not the way... contact or speak to at least one person today; family, a friend, new or old and make it count... I wish all the best... anyone can ping me at any time; Best Cliff

20/05/2026

16/05/2026

Scientists uncover the protein link that spreads Parkinson’s — and we have a drug that blocks it.
A new discovery could significantly alter the landscape of Parkinson’s disease treatment—using a drug that’s already FDA-approved.

07/05/2026

Breaking News: FDA Approved Staged Bilateral Focused Ultrasound for Parkinson’s Disease!

FDA Approved Staged Bilateral Focused Ultrasound for Parkinson’s Disease: Bringing Hope to Patients
Living with Parkinson’s Disease (PD) can be really tough, especially when tremors interfere with everyday activities. Initially, the Focused Ultrasound procedure was only approved to target one side of the body, offering some relief but often leaving individuals with persistent bilateral symptoms, still experiencing tremors on one side of their body.

Now, there’s some exciting news: the FDA has given the green light for staged bilateral Focused Ultrasound for Parkinson’s Disease. This advancement means eligible patients now have a new, non-invasive option to tackle tremors on both sides of their body.
-
-
Source: https://tinyurl.com/Parkinsonsprotocols

07/05/2026

📢 Big News in Focused Ultrasound for Parkinson’s Disease!

Parkinson’s disease (PD) patients can now get focused ultrasound treatment on both sides of the brain. The US FDA has approved INSIGHTEC Exablate Neuro for staged bilateral pallidothalamic tractotomy (PTT) in patients with advanced PD. This expanded approval covers both the initial and subsequent staged procedures for those experiencing severe motor symptoms like rigidity, bradykinesia, and dyskinesia due to PD.

“This is a tremendous milestone for not only the field of focused ultrasound but also patients suffering from this debilitating disease,” said Foundation Chairman Neal F. Kassell, MD. “We congratulate the team at Insightec and recognize that this would not be possible without the innovative spirit of so many researchers, including Daniel Jeanmonod, MD, who successfully pioneered this PTT technique.”

Read the full announcement: https://tinyurl.com/Parkinsonsprotocols

07/05/2026

FDA Expands Use of Focused Ultrasound for Parkinson’s
The FDA has approved bilateral focused ultrasound treatment for Parkinson’s disease (PD). Patients with advanced PD now have the option to receive focused ultrasound on both sides of their brain in two sessions at least six months apart. This ruling is an important milestone for patients, as PD is a systemic disease with symptoms including rigidity and dyskinesia that can impact the whole body.
The technology was initially cleared by the FDA to treat PD on one side in 2021.
Learn more: https://tinyurl.com/Parkinsonsprotocols
-
-
-

03/05/2026

This isn’t motivation… it’s survival.
Some days Parkinson’s wins a round.
But I keep getting back up.
I’m still here. I’m still fighting.
If you know what that feels like—comment “STILL HERE” 💪
Let’s stand together.🔥🧠💪
— Mark Effrig

02/05/2026

A single jab a week could wipe out the burden of Parkinson’s meds.
A weekly injectable drug developed in Australia may soon transform life for millions living with Parkinson’s disease.
Researchers at the University of South Australia have created a slow-release formulation of levodopa and carbidopa—the cornerstone medications for Parkinson’s—delivered through a biodegradable gel implant.
This gel, injected under the skin or into muscle, steadily releases the drugs over seven days, ensuring stable symptom control and reducing the side effects and inconvenience linked to taking pills several times a day. The innovation could be especially beneficial for older patients or those with difficulty swallowing.

In lab tests, the gel safely released more than 90% of its medication over a week and showed no signs of toxicity. Designed to be administered with a standard syringe and requiring no surgery, this in-situ forming implant avoids the complications of earlier drug delivery systems. Lead researcher Professor Sanjay Garg emphasized that the goal is to improve patient compliance and quality of life through more consistent dosing. Human trials are the next step, and if successful, this injectable could replace daily medication and open new avenues for treating other chronic conditions with long-acting therapies.
Source:

Nakmode, D.D., Abdella, S., Song, Y. et al. Development of an in-situ forming implant system for levodopa and carbidopa for the treatment of parkinson’s disease. Drug Deliv. and Transl. Res. (2025)
-
-
Source: https://tinyurl.com/Parkinsonsprotocols

01/05/2026

What is the main reason for Parkinson's?